BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Down 11.2% in November

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 18,490,000 shares, a decline of 11.2% from the October 31st total of 20,830,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the days-to-cover ratio is presently 9.3 days.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its stake in BioCryst Pharmaceuticals by 15.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 130,775 shares of the biotechnology company’s stock valued at $665,000 after buying an additional 17,091 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 62.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 156,119 shares of the biotechnology company’s stock valued at $793,000 after acquiring an additional 59,722 shares in the last quarter. Tidal Investments LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at $282,000. CWM LLC boosted its position in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares in the last quarter. Finally, Diversified Trust Co grew its position in BioCryst Pharmaceuticals by 18.0% in the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock worth $153,000 after buying an additional 3,774 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded down $0.10 during trading on Tuesday, reaching $7.28. The stock had a trading volume of 430,168 shares, compared to its average volume of 2,885,804. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $8.88. The firm’s 50 day moving average price is $7.59 and its two-hundred day moving average price is $7.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the previous year, the firm earned ($0.19) EPS. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. As a group, equities research analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BCRX. Barclays raised their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. JMP Securities lifted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.